Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants

作者:Laurie Cathy C; Laurie Cecelia A; Smoley Stephanie A; Carlson Erin E; Flinn Ian; Fridley Brooke L; Greisman Harvey A; Gribben John G; Jelinek Diane F; Nelson Sarah C; Paietta Elisabeth; Schaid Dan; Sun Zhuoxin; Tallman Martin S; Weinshilboum Richard; Kay Neil E; Shanafelt Tait D
来源:Cancer Genetics, 2014, 207(1-2): 19-30.
DOI:10.1016/j.cancergen.2014.01.004

摘要

Pretherapy patients with chronic lymphocytic leukemia (CLL) from US Intergroup trial E2997 were analyzed with single nucleotide polymorphism microarrays to detect acquired chromosomal anomalies. The four CLL-typical anomalies (11q-, +12, 13q-, and 17p-) were found at expected frequencies. Acquired anomalies in other regions account for 70% of the total detected anomalies, and their number per participant has a significant effect on progression-free survival after adjusting for the effects of 17p-(and other covariates). These results were compared with those from a previous study of more than 50,000 participants from the GENEVA consortium of genome-wide association studies, which analyzed individuals with a variety of medical conditions and healthy controls. The percentage of individuals with acquired anomalies is vastly different between the two studies (GENEVA 0.8%; E2997 80%). The composition of the anomalies also differs, with GENEVA having a higher percentage of acquired uniparental disomies and a lower percentage of deletions. The four common CLL anomalies are among the most frequent in GENEVA participants, some of whom may have CLL-precursor conditions or early stages of CLL. However, the patients from E2997 (and other studies of symptomatic CLL) have recurrent acquired anomalies that were not found in GENEVA participants, thus identifying genomic changes that may be unique to symptomatic stages of CLL.

  • 出版日期2014-2